Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy

Zeina M. Nabhan, Lori K.St Dennis Feezle, Allen R. Kunselman, Nancy B. Johnson, Peter A. Lee

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Aim: To evaluate adult height (AH) among girls with central precocious puberty (CPP) treated with gonadotropin releasing hormone analog (GnRHa) and to assess the impact of post-treatment growth on AH. Study design: Medical records of girls with CPP were reviewed. Results: Twenty-six girls aged 7.2 ± 2.0 years were identified. There was a significant difference between AH and predicted adult height (PAH) at the initiation of therapy (p = 0.005). Using univariate analysis, the only factor associated with AH was total growth after discontinuation of therapy. Growth after discontinuation of therapy was variable and often greater than expected. Both age and skeletal age at the end of therapy had strong linear relationships with growth after therapy explaining 60% of this growth. Conclusion: This report confirms that AH is normal among females with CPP treated in a timely fashion with GnRHa. The lack of pre-dictability of growth after discontinuation of therapy suggests that the decision to stop treat-ment should be individualized.

Original languageEnglish (US)
Pages (from-to)309-316
Number of pages8
JournalJournal of Pediatric Endocrinology and Metabolism
Volume22
Issue number4
DOIs
StatePublished - Apr 2009

Keywords

  • Central precocious puberty
  • Final adult height
  • GnRa therapy

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy'. Together they form a unique fingerprint.

Cite this